Palladio Biosciences was featured in the Emerging Company Profile section of the March 8, 2018 edition of BioCentury. The full…
–Data to be presented at ASN support the continued development of lixivaptan for polycystic kidney disease– NEWTOWN, PA: November…
– Orphan drug designation an important milestone for lixivaptan development program – Newtown, PA: October 4, 2017. Palladio Biosciences, Inc. (Palladio), a…
— Addition of Polycystic Kidney Expertise to Leadership Team — Newtown, PA: June 12, 2017. Palladio Biosciences, Inc. (Palladio) https://palladiobio.com/,…
— Repositioning Lixivaptan for Polycystic Kidney Disease — Newtown, PA: May 23, 2017. Palladio Biosciences, Inc. (Palladio) https://palladiobio.com/, a private…
Palladio Biosciences, Inc. Named “Best in Show” at Mid-Atlantic Bio Angels 1st Pitch Philadelphia Event – Press Release